Tests a surgical glue in the pancreas join during surgery for pancreatic cancer
Tests a surgical glue on the pancreas join in adults with soft pancreas.
Plain-language title generated from the registry record
Registry title: Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
Key facts
- Where
- Minya, EgyptSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07155525, who can take part
Where in Egypt
- Liver and GIT hospital , Minia UniversityMinya, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Minia University
- Trial code
- NCT07155525
- Record updated
- 1 October 2026
- Original description
This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing postoperative pancreatic fistula (POPF) in patients undergoing pancreaticoduodenectomy with soft pancreatic texture. The primary endpoint is the incidence of postoperative pancreatic fistula at 30 days post-surgery, as defined by the International Study Group on Pancreatic Fistula (ISGPF) criteria.Secondary outcomes include surgical complications and length of hospital stay. The study will enroll approximately 194 patients at a single center.Read full original descriptionShow less
Pancreaticojejunostomy With or Without Modified N-butyl-2-cyanoacrylate Following Pancreaticoduodenectomy in Soft Pancreas: Randomized Controlled Trial
This is a single-center, randomized controlled trial comparing the efficacy of pancreaticojejunostomy with modified N-butyl-2-cyanoacrylate(Glubran® 2) versus standard pancreaticojejunostomy without cyanoacrylate in preventing postoperative pancreatic fistula (POPF) in patients undergoing pancreaticoduodenectomy with soft pancreatic texture. The primary endpoint is the incidence of postoperative pancreatic fistula at 30 days post-surgery, as defined by the International Study Group on Pancreatic Fistula (ISGPF) criteria.Secondary outcomes include surgical complications and length of hospital stay. The study will enroll approximately 194 patients at a single center.
Inclusion: Patients scheduled for elective pancreaticoduodenectomy for malignant lesions; Intraoperative confirmation of soft pancreatic texture (by surgeon palpation; friable, non-fibrotic pancreas); Age 18-75 years ; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Adequate organ function defined as:; Hemoglobin ≥ 9.0 g/dL Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 100,000/μL Total bilirubin ≤ 3 times upper limit of normal Alanine transaminase (ALT) /Alanine transaminase (ALT)( ≤ 5 times upper limit of normal Serum creatinine ≤ 1.5 times upper limit of normal; Informed consent provided; Willingness to comply with study procedures and follow-up requirements.
Exclusion: Emergency surgery; Previous pancreatic surgery or pancreatic anastomosis; Intraoperative identification of unresectable disease; Known allergy to cyanoacrylate or components; Active infection or sepsis; Hard pancreatic texture (intraoperative surgeon assessment); Pregnancy or lactation; Inability to comply with follow-up.